BeOne Medicines discloses H1 2026 R&D spend of $1.15B, up 14.6% YoY

BeOne Medicines Ltd.

2026-Q2 EPS reported $0.31 revenue$3,218,509,000

Total R&D expense $1,153.5M in H1 2026 vs $1,006.8M in H1 2025, up 14.6% YoY.
BRUKINSA R&D fell 33% to $42.7M from $63.0M; TEVIMRA down to $37.1M from $40.3M.
BEQALZI (sonrotoclax) R&D $74.0M, down 21%; BGB-43395 CDK4 inhibitor surged to $22.7M vs $9.9M.
Early-stage spend jumped: BGB-58067 $11.1M vs $1.9M, BG-C9074 $8.2M vs $2.4M, tacabrutideg $44.3M vs $26.9M.
External R&D $435.1M vs $400.3M; internal R&D $718.4M vs $606.5M a year ago.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.